189 related articles for article (PubMed ID: 16631354)
1. Long-term combination antipsychotic treatment in VA patients with schizophrenia.
Kreyenbuhl J; Valenstein M; McCarthy JF; Ganoczy D; Blow FC
Schizophr Res; 2006 May; 84(1):90-9. PubMed ID: 16631354
[TBL] [Abstract][Full Text] [Related]
2. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns.
Kreyenbuhl JA; Valenstein M; McCarthy JF; Ganoczy D; Blow FC
Psychiatr Serv; 2007 Apr; 58(4):489-95. PubMed ID: 17412850
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia.
Gören JL; Meterko M; Williams S; Young GJ; Baker E; Chou CH; Kilbourne AM; Bauer MS
Psychiatr Serv; 2013 Jun; 64(6):527-33. PubMed ID: 23450334
[TBL] [Abstract][Full Text] [Related]
4. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
Constantine RJ; Andel R; McPherson M; Tandon R
Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
[TBL] [Abstract][Full Text] [Related]
5. Maintenance phase treatment of psychotic disorders in outpatients from Serbia - focus on long-term benzodiazepine use.
Marić NP; Andrić Petrović S; Jerotić S; Ristić I; Savić B; Zebić M; Vuković V; Britvić D; Golubović O; Jakšić M; Jevđić K; Kolašinac Z; Lalović N; Mirković Ilić J; Nikolić S; Paunović Č; Pavlović Z; Pejović Nikolić S; Perović V; Popović J; Ranđić Avakumović V; Stojanović S; Tatarević M; Živković I; Voskresenski T; Jovanović N
Int J Psychiatry Clin Pract; 2020 Sep; 24(3):315-321. PubMed ID: 32459564
[No Abstract] [Full Text] [Related]
6. Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study.
Sneider B; Pristed SG; Correll CU; Nielsen J
Eur Neuropsychopharmacol; 2015 Oct; 25(10):1669-76. PubMed ID: 26256007
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.
Ganguly R; Kotzan JA; Miller LS; Kennedy K; Martin BC
J Clin Psychiatry; 2004 Oct; 65(10):1377-88. PubMed ID: 15491242
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary.
Katona L; Czobor P; Bitter I
Schizophr Res; 2014 Jan; 152(1):246-54. PubMed ID: 24275583
[TBL] [Abstract][Full Text] [Related]
9. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
10. Predictors of long-term (≥6months) antipsychotic polypharmacy prescribing in secondary mental healthcare.
Kadra G; Stewart R; Shetty H; Downs J; MacCabe JH; Taylor D; Hayes RD
Schizophr Res; 2016 Jul; 174(1-3):106-112. PubMed ID: 27091655
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic Polypharmacy Among Patients With Schizophrenia in Africa: A Systematic Review and Meta-Analysis.
Ayenew W; Asmamaw G; Bitew T
Int J Neuropsychopharmacol; 2021 Dec; 24(12):956-964. PubMed ID: 34245271
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic polypharmacy in older Australians.
Kalisch Ellett LM; Pratt NL; Kerr M; Roughead EE
Int Psychogeriatr; 2018 Apr; 30(4):539-546. PubMed ID: 29122047
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004.
Gilmer TP; Dolder CR; Folsom DP; Mastin W; Jeste DV
Psychiatr Serv; 2007 Jul; 58(7):1007-10. PubMed ID: 17602020
[TBL] [Abstract][Full Text] [Related]
14. Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014.
Fontanella CA; Hiance-Steelesmith DL; Guirgis H; Campo JV
Psychiatr Serv; 2018 Sep; 69(9):1015-1020. PubMed ID: 29962308
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan.
Qiu H; He Y; Zhang Y; He M; Liu J; Chi R; Si T; Wang H; Dong W
Aust N Z J Psychiatry; 2018 Dec; 52(12):1202-1212. PubMed ID: 30309245
[TBL] [Abstract][Full Text] [Related]
16. The hidden magnitude of polypharmacy: using defined daily doses and maximum licensed daily doses to measure antipsychotic load.
Nguyen ML; Sunderland B; Lim S; Hattingh L; Chalmers L
Int J Clin Pharm; 2019 Dec; 41(6):1642-1651. PubMed ID: 31677120
[TBL] [Abstract][Full Text] [Related]
17. Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders.
Abdel Aziz K; Mohd Ahmed H; Stip E; Aly El-Gabry D
Int Clin Psychopharmacol; 2024 Jul; 39(4):257-266. PubMed ID: 38381917
[TBL] [Abstract][Full Text] [Related]
18. Subjective Medication Satisfaction With Antipsychotic Polypharmacy in a Naturalistic Inpatient and Outpatient Sample.
Kikkert MJ; de Mooij L; de Koning M; Dekker J
J Clin Psychiatry; 2021 Dec; 83(1):. PubMed ID: 34936243
[No Abstract] [Full Text] [Related]
19. Description of long-term polypharmacy among schizophrenia outpatients.
Suokas JT; Suvisaari JM; Haukka J; Korhonen P; Tiihonen J
Soc Psychiatry Psychiatr Epidemiol; 2013 Apr; 48(4):631-8. PubMed ID: 23007295
[TBL] [Abstract][Full Text] [Related]
20. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries.
Barbui C; Nosè M; Mazzi MA; Thornicroft G; Schene A; Becker T; Bindman J; Leese M; Helm H; Koeter M; Weinmann S; Tansella M
Int Clin Psychopharmacol; 2006 Nov; 21(6):355-62. PubMed ID: 17012982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
